However, existing HDAC inhibitors can exhibit low potency, lack of selectivity, and poor pharmacokinetic or toxicity profiles.

但现有HDAC抑制剂效度低、缺乏选择性、药代动力学或毒性特征较差。

youdao

However, existing HDAC inhibitors can exhibit low potency, lack of selectivity, and poor pharmacokinetic or toxicity profiles.

但现有HDAC抑制剂效度低、缺乏选择性、药代动力学或毒性特征较差。

youdao